MedTrace Logo

Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients

NCT01656343 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 775

Last updated 2022-07-22

No results posted yet for this study

Summary

* To estimate the incidence rates of post-transplant lymphoproliferative disorder (PTLD) in adult, EBV seropositive, kidney alone transplant recipients treated with belatacept at the time of transplantation
* To estimate the incidence rates of PTLD in adult, EBV seropositive, kidney alone transplant recipients treated with calcineurin inhibitors (CNI)-based regimens at the time of transplantation
* To compare the PTLD incidence rates in adult, EBV seropositive, kidney alone transplant recipients treated with belatacept to the rates in adult, EBV seropositive, kidney alone transplant recipients treated with CNI-based regimens at the time of transplantation

Conditions

  • Kidney Transplantation
  • Transplantation, Kidney

Interventions

DRUG

Calcineurin inhibitors (CNI)

No Intervention

DRUG

Belatacept

No Intervention

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2019-08-05
Completion
2019-08-05

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01656343 on ClinicalTrials.gov